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Objective: Rituximab is a commonly used treatment for CD20-positive B-cell lymphoma. Late onset
neutropenia (LON) has been identiﬁed as a complication associated with rituximab. FcgRIIIa 158 V/F
polymorphism has been correlated with LON. We want to explore the relation between FcgRIIIa 158 V/F
polymorphism and survival outcome.
Materials and Methods: We examined a cohort of patients with newly diagnosed CD20-positive B-cell
lymphoma who were treated with rituximab-based therapy. We identiﬁed patients with LON and
analyzed their characteristics and survival outcomes. Furthermore, we used a multiplex polymerase
chain reaction to detect FcgRIIIa 158 V/F polymorphism and correlated this with LON. After a 10-year
follow-up, we analyzed the survival outcomes between groups with different FcgRIIIa polymorphisms.
Results: Seventy-two consecutive patients with CD20-positive B-cell lymphoma patients were examined.
Eleven (15.2%) of these patients developed LON. The V/V and V/F polymorphisms were signiﬁcantly
associated with the occurrence of LON (p ¼ 0.031), yielding an odds ratio for the development of LON of
1.47 (95% conﬁdence interval, 1.21e1.78). The log-rank test showed no overall survival difference both in
the occurrence of LON and different polymorphisms.
Conclusion: The FcgRIIIa polymorphism was signiﬁcantly associated with development of LON. Further-
more, neither FcgRIIIa polymorphism nor LON predicted a patient’s survival outcome according to the
results of a long-term follow-up study.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
Rituximab is a genetically engineered chimeric murine/human
monoclonal antibody that is directed to the CD20 antigen, which is
found on the surface of premature and mature B cells. Rituximab
has proven efﬁcacy in the treatment of CD20-positive B cellOncology, Department of In-
tal, 2, Min-Sheng Road, Dalin,
6 5 2648006.
).
ddhist Compassion Relief Tzu Chilymphoma. It works in the indolent and aggressive histological
types, and also in untreated or relapsing populations [1]. Therefore,
rituximab has become widely used. Currently, inclusion of ritux-
imab is the standard treatment for CD20-positive B cell lymphoma.
Late onset neutropenia (LON) is a well-recognized late compli-
cation of rituximab-based chemotherapy. There is currently no
uniform deﬁnition of LON [2], but it is generally deﬁned as the
unexplained occurrence of neutropenia at least 4 weeks after the
completion of rituximab administration and full hemogram re-
covery [3,4]. Rituximab-related LON has been reported as a rare
late-onset complication. As awareness of this adverse effect in-
creases, the incidence of LON has been reported to range from 5.6%Foundation. Published by Elsevier Taiwan LLC. All rights reserved.
Table 1
FCgRIIIa polymorphism versus late onset neutropenia (LON).
Variable V/V V/F F/F Total
Number Number Number
LON 2 9 0 11
No LON 5 37 19 61
LON/(LON þ No LON) 28.6% 19.6% 0%
Total 7 46 19 72
Table 2
Demographic characteristic of patients included in the study (n ¼ 72).
Variable VF/VV FF p
Number (%) Number (%)
Age (y), mean  SD 61.29  15.38 62.26  13.99 0.809
Gender
Male 25 (47) 10 (53) 0.683
Female 28 (53) 9 (47)
Hypertension
Yes 6 (11) 7 (37) 0.013
No 47 (89) 12 (63)
Diabetes mellitus
Yes 9 (17) 4 (21) 0.692
No 44 (83) 15 (79)
Hepatitis B carrier
Yes 11 (21) 4 (21) 0.978
No 42 (79) 15 (79)
Hepatitis C
Yes 8 (15) 1 (5) 0.266
No 45 (85) 15 (95)
IPI score
0e1 18 (34) 7 (37) 0.821
2e4 35 (66) 12 (63)
Histology type
Aggressive 45 (85) 16 (84) 0.942
Indolent 8 (15) 3 (16)
Stage
IeII 27 (51) 7 (37) 0.291
IIIeIV 26 (49) 12 (63)
Bone marrow involvement
Yes 9 (17) 5 (26) 0.378
No 44 (83) 14 (74)
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populations.
The mechanism underlying LON is still unknown. Several sus-
picious etiologies of LON have been discussed, including super-
imposed infections, the bystander effect, and lymphocyte
subpopulation imbalance [10]. The known risk factors for LON
include intensiﬁed treatment and advanced disease status.
FcgRs have been shown to mediate phagocytosis, antibody-
dependent cell-mediated cytotoxicity, and other inﬂammatory
mediators central to the protective and injurious properties of an-
tibodies [11]. Immunoglobulin G (IgG) Fc receptor (FcR) poly-
morphisms that inﬂuence the binding of IgG have been described
[12e14]. A polymorphism of FcgRIIIa has been identiﬁed at posi-
tion 158 with a V or F residue, and it was reported that the FcgRIIIa
158 V allele is associated with rituximab-induced LON after autol-
ogous hematopoietic stem cell transplantation [15].
We previously reported an 11.3% incidence in LON following
frontline rituximab-based treatment in a large cohort of patients
with newly diagnosed CD20-positive B cell lymphoma. The FcgRIIIa
158 V/V and V/F polymorphisms were signiﬁcantly associated with
the development of rituximab-related LON [16]; however, the data
addressing the correlations between long-term survival and
occurrence of LON and FcgRIIIa 158 V/F polymorphism have not
been discussed.
According to the extended data, we determined whether the
FcgRIIIa 158V/F polymorphism or LON is correlated with clinical
outcomes in patients diagnosed with CD20-positive B cell lym-
phoma who received rituximab-based chemotherapy.
2. Materials and methods
A total of 100 newly diagnosed patients with CD20-positive B
cell lymphoma who received rituximab-based chemotherapy at a
single institution between April 2003 and January 2009 were
included in this prospective cohort study. The diagnosis of B cell
lymphoma, including the aggressive and indolent histology types,
was based on the pathologist’s determination and expression of
CD20 on the lymphoma cell. After giving informed consent, pa-
tients were enrolled in the observative cohort study. Blood sam-
pling for genetic study was optional. The deﬁnition of LON in our
study included the following criteria: (1) an absolute neutrophil
count <1500/mL; (2) neutropenia occurring >4 weeks after the last
rituximab-based treatment; and (3) exclusion of an alternative
etiology of neutropenia. Exclusion criteria were as follows: (1)
cirrhosis (hepatitis B- or C-related); (2) neutropenia (<1500/mL)
before the ﬁrst cycle of chemotherapy; and (3) concurrent use of
medications that may cause neutropenia. After completion of
frontline therapy, all patients had complete blood counts every 2e3
weeks for 6 months. Furthermore, patients who developed LON
continued to receive close follow-up in the outpatient clinic (1 visit
every 1e2 weeks) with a complete blood count every 2 weeks until
full neutrophil recovery. The study was approved by the Tzu Chi
Dalin General Hospital institutional review board.
Heparinized blood samples were collected from all patients who
gave informed consent. Genomic DNA was extracted from periph-
eral blood mononuclear cells using a DNA extraction kit. A poly-
merase chain reaction-based method to determine FcgRIIIa
genotypes was used, as previously described [17].
The mean values and standard deviations were calculated to
describe the data population. The Pearson chi-square test was used
to evaluate the distribution of the two groups (dividing the three
genotypes into VV/VF vs. FF) between each group. Statistical ana-
lyses were performed using the Fisher exact test or two-tailed t-
test. Multiple clinical factors (gender, age, history of hepatitis C
virus infection, history of hepatitis B virus infection, chemotherapyregimen, and lymphoma histology) were evaluated using univari-
ate analyses with Cox proportional hazards regression for in-
dicators suggesting the development of LON. Survival and follow-
up times were calculated from the day of pathologic diagnosis to
the day of last follow-up or death. We used commercial statistical
software (SPSS version 17.0; SPSS Inc., Chicago, IL, USA) to perform
statistical analyses. Different groups were compared with respect
to baseline characteristics using a t-test for continuous variables
and the chi-square test for categorical variables. The KaplaneMeier
method was used for survival analysis. A p value <0.05 was
considered statistically signiﬁcant.3. Results
A cohort of 100 newly diagnosed patients with CD20-positive B
cell lymphoma were consecutively treated with rituximab-
containing chemotherapy without autologous stem cell trans-
plantation. Because blood sampling was not enforced, only 72 pa-
tients with FCgRIIIa 158 V allele polymorphismwere available after
completion of informed consent. We performed a subgroup anal-
ysis of these 72 patients to interpret the association between
FCgRIIIa 158 V allele polymorphism, LON, and survival outcome.
Among the patients, 11 (15.2%) who received rituximab-
containing chemotherapy developed LON. In the LON group, two
Fig. 1. Overall survival curves for lymphoma cancer according to VF type.
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polymorphism, and none had the FcgRIIIa 158 F/F polymorphism. In
the non-LON group, ﬁve patients had the V/V polymorphism, 37
patients had the V/F polymorphism, and 19 patients had the
FcgRIIIa 158 F/F polymorphism (Table 1). The prevalence rate of
LON was 28.6% among patients in the FcgRIIIa 158 V/V group, 19.6%
in the FcgRIIIa 158 V/F group, and 0% in the FcgRIIIa 158 F/F group.
The FCgRIIIa 158 allele polymorphism was divided into two
groups (V/V, V/F vs. F/F). Because the sample size was too small for
comparison, we combined the VV/VF group and compared the VV/
VF group with the F/F group. The patient baseline characteristics
are presented in Table 2. The characteristics of the treatment mo-
dality and treatment responses are listed in Table 3. There were no
differences in baseline data, comorbidities, histologic types, clinical
stages, prognostic indices, or rituximab-based chemotherapy
regimen, although there were slightly more patients with hyper-
tension (Table 2, hypertension, p ¼ 0.013) in the FF group than the
VV/VF group. In contrast, the occurrence of late onset neutropenia
(p ¼ 0.031) and the complete response rate were higher in the VV/
VF group. Patients with VV/VF had a signiﬁcantly increased rate of
LON compared with the F/F group (p ¼ 0.031). The odds ratio for
VV/VF patients to develop LON was 1.263 (95% conﬁdence interval,
1.098e1.449).
We next estimated the overall survival of the FcgRIIIa poly-
morphism groups. There were no signiﬁcant differences between
patients with the FcgRIIIa F/F polymorphism and patients with the
V/F or V/V genotype (p ¼ 0.649; Fig. 1). We further examined the
survival of patients with or without LON. Similarly, there was no
difference in survival between patients who did and did not have
LON (p ¼ 0.563; Fig. 2). There were also no differences in the
progression-free survival between FcgRIIIa polymorphism groups,
or between patients with and without LON (Figs. 3 and 4).
Analysis of the major prognostic factors based on univariate Cox
regression analysis showed that age and initial treatment response
were correlated with better survival outcomes, rather than the
international prognostic index score, histology type, gender, LON,
or FcgRIIIa polymorphism (Table 4).
4. Discussion
This is the ﬁrst prospective cohort study to interpret the cor-
relation between survival outcome and occurrence of LON in pa-
tients with newly diagnosed CD20-positive B cell lymphoma, whoTable 3
Therapeutic regimen and outcome (n ¼ 72).
Variable VF/VV FF p
Number (%) Number (%)
CHOP-like regimen
Yes 46 (87) 16 (84) 0.780
No 7 (13) 3 (16)
ESHAP/EPOCH
Yes 20 (38) 11 (58) 0.128
No 33 (62) 8 (42)
Other regimen
Yes 15 (28) 8 (42) 0.268
No 38 (72) 11 (58)
Late onset neutropenia
Yes 11 (21) 0 (0) 0.031
No 42 (79) 19 (100)
Initial treatment response
CR 42 (79) 13 (68) 0.341
Non-CR 11 (21) 6 (32)
Final disease status
CR 29 (55) 5 (26) 0.033
Non-CR 24 (45) 14 (74)were treated with rituximab-based chemotherapy without salvage
high-dose chemotherapy plus autologous stem cell rescue. The
follow-up period was up to 10 years in length.
We previously showed that rituximab-induced LON was corre-
lated with FcgRIIIa genotypes in patients with CD20-positive B cell
lymphoma. The objective of this clinical study was to lay a foun-
dation for the clinical results. Again, the occurrence of LON was
signiﬁcantly associated with FCgRIIIa 158 V allele polymorphism.
Neither LON nor FCgRIIIa 158 V allele polymorphism showed a
survival effect.
The incidence of LON has been reported to range widely be-
tween 5.6% and 27.3% [3,5,8,9,18e20] in separate series, probably
because of various deﬁnitions of rituximab-associated LON and
different patient populations. The incidence of LON in the current
extended study involving patients with untreated CD20-positive B
cell lymphoma was 15.2% (11 of 72 patients). The prevalence wasFig. 2. Survival curves for lymphoma cancer according to LON status., LON ¼ late onset
neutropenia.
Fig. 3. Progression-free survival curves for lymphoma cancer according to VF type.
Table 4
Univariate analysis.
Variable Death event (%) HR 95% CI p
VF type
VF/VV 27/53 (51) 1 0.649
FF 10/19 (53) 1.18 (0.57e2.45)
Age (y) 1.04 (1.01e1.06) 0.006
Gender
Male 19/35 (49) 1.34 (0.70e2.57) 0.376
Female 18/37 (54) 1
IPI score
0e1 11/25 (44) 1 0.661
2e4 26/47 (55) 1.17 (0.57e2.40)
Histology type
Aggressive 33/61 (54) 1 0.138
Indolent 4/11 (36) 0.45 (0.16e1.29)
Initial treatment response
CR 22/55 (40) 0.18 (0.09e0.35) <0.001
No CR 15/17 (88) 1
LON
Yes 5/11 (14) 0.76 (0.29e1.95) 0.565
No 32/61 (86) 1
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patients) [16]. The difference in the current study was attributed to
not excluding patients with bonemarrow involvement and analysis
of FCgRIIIa 158 V allele polymorphism. The above prevalence rates
of LON were based on different deﬁnitions, which were similar and
within the range of previously published data [3,5,8,19].
Keaneet al [21] reportedaprospective studywitha5-year follow-
up period, and determined outcomes in 115 patients with newly
diagnosed diffuse large B cell lymphoma who received uniform rit-
uximab-cyclophosphamide/hydroxydaunorubicin/oncovin/predni
sone. Keane et al [21] reported that FCgRIIIa 158 V/V was highlyFig. 4. Progression-free survival curves for lymphoma cancer according to LON status.
LON ¼ late onset neutropenia.correlated with the prevalence of LON. LON and FCgRIIIa poly-
morphism did not predict overall survival and progression-free
survival. Although there were several minor differences in enrolled
populations and interventions, the results were not in conﬂict with
the results reported in this study.
Hincks et al [22] concluded that the occurrence of LON predicted
the better response to rituximab-based chemotherapy. This argu-
ment was based on the observation that only one patient failed to
achieve a complete response among 92 patients with LON from
several retrospective studies. Similarly, in the current study, only
one of 11 patients with LON did not achieve a complete response.
However, up to ﬁve of 10 patients who achieved complete remis-
sion had recurrence of disease during the follow-up period.
Furthermore, only one patient with recurrent lymphoma achieved
complete remission again. According to the above description, we
hypothesize that rituximab might enhance the response of ritux-
imab in patients with LON but not against the natural resistance of
underlying malignancy.
There were several limitations in the current research. First, our
study included patients with heterogenous pathological diagnoses,
which included aggressive and indolent lymphoma with totally
different disease characteristics and nature course. It is not feasible
to interpret the clinical impact of FCgRIIIa 158 V allele poly-
morphism in speciﬁc lymphoma entities. Second, there were con-
founding factors from heterogenous treatment regimens. Third,
lack of cases with salvage high-dose chemotherapy plus autologous
stem cell rescue does not fully match current clinical practice. The
role of LON in patients with autologous stem cell transplantation
should be further determined.
5. Conclusion
Our study demonstrated that the presence of the FCgRIIIa 158 V
allele predicted the occurrence of LON. However, there was no
prognostic relevance between FCgRIIIa polymorphism and newly
diagnosed CD20-positive B cell lymphoma in patients who received
rituximab-based chemotherapy. Larger studies are needed for a
deﬁnite conﬁrmation of the clinical applicability and prognostic
signiﬁcance of FCgRIIIa polymorphisms.
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